Search by Drug Name or NDC
NDC 70710-1411-01 BORTEZOMIB 1 mg/mL Details
BORTEZOMIB 1 mg/mL
BORTEZOMIB is a INTRAVENOUS; SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals USA Inc.. The primary component is BORTEZOMIB.
MedlinePlus Drug Summary
Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system). Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells.
Related Packages: 70710-1411-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Bortezomib
Product Information
| NDC | 70710-1411 |
|---|---|
| Product ID | 70710-1411_77554fd4-a569-4180-9a5f-e51962f8524b |
| Associated GPIs | 21536015002120 |
| GCN Sequence Number | 052124 |
| GCN Sequence Number Description | bortezomib VIAL 3.5 MG INJECTION |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 19656 |
| HICL Sequence Number | 025202 |
| HICL Sequence Number Description | BORTEZOMIB |
| Brand/Generic | Generic |
| Proprietary Name | BORTEZOMIB |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | BORTEZOMIB |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS; SUBCUTANEOUS |
| Active Ingredient Strength | 1 |
| Active Ingredient Units | mg/mL |
| Substance Name | BORTEZOMIB |
| Labeler Name | Zydus Pharmaceuticals USA Inc. |
| Pharmaceutical Class | Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210204 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 70710-1411-01 (70710141101)
| NDC Package Code | 70710-1411-1 |
|---|---|
| Billing NDC | 70710141101 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-1411-1) / 3.5 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2022-05-02 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |